Who can use Tabrecta(Capmatinib)?

A treatment for metastatic NSCLC harboring a specific MET gene mutation.

Indications

TABRECTA is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC). Its use is strictly reserved for patients whose tumors have a confirmed mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping. This mutation must be detected using an FDA-approved test. Prior to initiating treatment, patient selection through biomarker testing of tumor tissue or plasma specimens is mandatory to identify this specific genetic alteration.